Salt Lake City, Utah — October 16, 2025 — Leads & Copy — SINTX Technologies, Inc. (NASDAQ: SINT) has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering the Company’s antipathogenic fabric technology.
According to the company, this development expands the Company’s Intellectual Property (IP) to protect both the material itself and the processes that bring it to market. These two patent families create a comprehensive IP competitive barrier around SINTX’s surface-level pathogen-inactivation technology, covering applications in wound dressings, surgical drapes and gowns, filtration media, personal protective equipment (PPE), and high-touch clinical surfaces.
Eric K. Olson, Chairman and CEO of SINTX Technologies said that the newly allowed patent complements the recently issued U.S. Patent No. 12,433,356, granted on October 7, 2025, which covers the composition of silicon nitride for antipathogenic fibrous materials. Lisa Marie, Del Re, Chief Commercial Officer, added that with method claims, the company can now defend and license the manufacturing and application pathways that unlock silicon nitride’s antipathogenic performance in textiles and surfaces.
Dr. Ryan Bock, Chief Technology Officer, said that peer-reviewed work has repeatedly shown rapid inactivation of coronaviruses and broad antimicrobial activity associated with silicon nitride, including recent data reporting up to ~99.97% reduction of infectious SARS-CoV-2 within minutes under lab conditions.
SINTX plans to pursue licensing and co-development partnerships with textile, wound care, and filtration/PPE partners.
Contact:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
Sintx@kcsa.com
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
Source: SINTX Technologies, Inc.
